SILO PHARMA, INC. Marketable Securities, Unrealized Gain (Loss)
SILO PHARMA, INC. (SILO) reported Marketable Securities, Unrealized Gain (Loss) of -$331.20 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-24.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2023-03-24
- SILO PHARMA, INC. marketable securities, unrealized gain (loss) for the quarter ending 2022-12-31 was -$74.82K.
- SILO PHARMA, INC. marketable securities, unrealized gain (loss) for the quarter ending 2022-09-30 was -$35.07K.
- SILO PHARMA, INC. marketable securities, unrealized gain (loss) for the quarter ending 2022-06-30 was -$59.51K.
- SILO PHARMA, INC. marketable securities, unrealized gain (loss) for the quarter ending 2022-03-31 was -$161.80K.
- SILO PHARMA, INC. marketable securities, unrealized gain (loss) for fiscal 2022 was -$331.20K, a 233.23% decline from fiscal 2021.
- SILO PHARMA, INC. marketable securities, unrealized gain (loss) for fiscal 2021 was $248.59K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$74.82K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$109.89K derived: sum of 2 quarters · filed 2023-03-24 | -$169.41K derived: sum of 3 quarters · filed 2023-03-24 | -$331.20K 10-K · filed 2023-03-24 |
| 2022-09-30 | -$35.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$94.58K derived: sum of 2 quarters · filed 2022-11-10 | -$256.38K 10-Q · filed 2022-11-10 | -$377.42K derived: sum of 4 quarters · filed 2023-03-24 |
| 2022-06-30 | -$59.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-01 | -$221.31K 10-Q · filed 2022-08-01 | -$342.35K derived: sum of 3 quarters · filed 2023-03-24 | |
| 2022-03-31 | -$161.80K 10-Q · filed 2022-05-13 | -$282.84K derived: sum of 2 quarters · filed 2023-03-24 | ||
| 2021-12-31 | -$121.04K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $248.59K 10-K · filed 2023-03-24 | ||
| 2021-09-30 | $369.63K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |